Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database
Current Oncology · 2026
DOI: 10.3390/curroncol33100589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2026. Verfasst von Felipe Batalini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Hospital, Phoenix, AZ 85054, USA. Hauptthemen laut MEDLINE: Piperazines, Phthalazines, Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, Merck & Co., Merck & Co., Inc..
Abstract (Originalsprache)
Background and Objectives: As adjuvant treatment for human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer (eBC) evolves, real-world data should inform olaparib utilization, sequencing, and combination patterns in clinical practice.
Methods
Using Komodo US claims data (1 January 2019–31 December 2023), we retrospectively analyzed HER2-negative eBC patients on adjuvant olaparib. Continuous insurance for 12 months pre- and ≥30 days post-index date (first olaparib prescription), with follow-up through disenrollment or study end, was required. Outcomes, including time on therapy (Kaplan–Meier median persistence), adherence (proportion of days covered), dose reduction, and combination patterns, were stratified by claims-derived hormone-receptor-positive (HR+) and triple-negative BC (TNBC) status.
Results
Among 176 olaparib-treated patients (median age, 44 years), the median (95% CI) time on therapy was 11.0 (9.2, 12.2) months; 27.3% (n = 48) discontinued before 12 months without re-initiating, 19.9% experienced a dose reduction, and median adherence was 90%. Olaparib was combined with other therapies in 48.3% (n = 85) (29.6% [32/108] of TNBC and 77.9% [53/68] of HR+ patients), most often with immunotherapy in TNBC (81.3%, n = 26) and endocrine therapy in HR+ (88.7%, n = 47).
Conclusions
Real-world data suggest favorable persistence and dosing patterns with adjuvant olaparib. Future research should prioritize olaparib combination regimen safety and effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mayo Clinic Hospital, Phoenix, AZ 85054, USA.
- AstraZeneca, Gaithersburg, MD 20878, USA.
- Merck Sharp & Dohme LLC, A Subsidiary of Merck & Co., Inc., Rahway, NJ 07065, USA.
- Cencora, Conshohocken, PA 19428, USA.
ORCID-Profile: Felipe Batalini, Qixin Li, Neel Vaidya
Förderung
- AstraZeneca
- Merck & Co.
- Merck & Co., Inc.
Zitieren
APA
Batalini, F., Li, Q., Hayes, J. F., Mishkin, K., Vaidya, N., Stafkey, D., Farrelly, E., & Xu, X. (2026). Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database. Current Oncology. https://doi.org/10.3390/curroncol33100589
Vancouver
Batalini F, Li Q, Hayes JF, Mishkin K, Vaidya N, Stafkey D, et al. Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database. Current Oncology. 2026. doi:10.3390/curroncol33100589
BibTeX
@article{Batalini2026,
author = {Batalini, Felipe and Li, Qixin and Hayes, Jennifer F and Mishkin, Kathryn and Vaidya, Neel and Stafkey, Dana and Farrelly, Eileen and Xu, Xiaoqing},
title = {Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33100589}
}
EUVIMED